6-[(3-Phenylpropyl)(2-propylpentanoyl)amino]hexanoic acid | 90068-76-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-[(3-Phenylpropyl)(2-propylpentanoyl)amino]hexanoic acid
• 英文别名: 6-[3-phenylpropyl(2-propylpentanoyl)amino]hexanoic acid
• CAS: 90068-76-1
• 化学式: C₂₃H₃₇NO₃
• 分子量: 375.5
• InChiKey: YFCDJGPBCZRFAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist
  申请人：Lee G. Andrew

  公开号：US20050065133A1

  公开（公告）日：2005-03-24

  The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP 2 or EP 4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 and an EP 2 or EP 4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.

  本发明涉及制药组合物和治疗方法，包括向需要的患者施用2-烷基亚甲基-19-去氢维生素D衍生物和EP2或EP4选择性激动剂或其药用可接受的盐或前药的组合物。特别地，本发明涉及制药组合物和方法，包括向需要的患者施用2-亚甲基-19-去氢-20(S)-1α,25-二羟基维生素D3和EP2或EP4选择性激动剂或其药用可接受的盐或前药。
• Prevention of loss and restoration of bone mass by certain prostaglandin agonists
  申请人：——

  公开号：US20020016368A1

  公开（公告）日：2002-02-07

  Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

  前列腺素激动剂，使用这种前列腺素激动剂的方法，包含这种前列腺素激动剂的制药组合物和包含这种前列腺素激动剂的套装。这些前列腺素激动剂对于治疗骨疾病，包括骨质疏松症，非常有用。
• Method for treating glaucoma
  申请人：Pfizer Products Inc.

  公开号：EP1000619A2

  公开（公告）日：2000-05-17

  Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

  使用前列腺素激动剂降低眼内压和青光眼的方法。
• PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS
  申请人：PFIZER INC.

  公开号：EP0951282B1

  公开（公告）日：2008-04-02
• PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
  申请人：PFIZER INC.

  公开号：EP0946501A1

  公开（公告）日：1999-10-06